Announced Wed, 28 Oct, 2026 · 21:06 IST
Q2 revenue up 46%, PAT up 249%; Rs 574.6 cr stamp duty dispute flagged
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults RestatedExceptional ItemEmphasis Of MatterResults View source PDFExplain this filing
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Consolidated Q2 revenue rose 45.9% to Rs 610.5 cr and PAT jumped 248.8% to Rs 71.5 cr; H1 PAT was Rs 147.6 cr. Standalone Q2 PAT was Rs 65.8 cr, up 179.8%. A Rs 20.4 cr stamp duty provision was booked and Rs 574.6 cr disclosed as contingent liability and challenged in court. The auditor highlighted this and the restatement of prior Q2 and half-year figures. CFO Piyush Lakhani resigned; Vibha Thakkar takes over on 31 Oct 2026.
Likely market impact
Strong profit growth and higher margins should support the stock, but the Rs 574.6 cr stamp duty claim and CFO change add risk.